Unibest

管线数据库

UB251

Ceftazidime for Injection

提交项目新药候选物数据库

UB251

ProductCeftazidime for Injection
Strength0.5g; 1.0g; 1.5g; 2.0g; 2.5g
IndicationsSepsis; Lower respiratory tract infection; Intra-abdominal infection; Biliary tract infection; Complicated urinary tract infection; Skin and soft tissue infection; Opportunistic infection; Nosocomial infection; Central nervous system infection
TherapeuticsInfectious Diseases
GMPCN - NMPA; JP - PMDA
RegistrationJapan
ModalitiesSmall Molecule

Exclusive Summary

  • - Originator patents expired long ago (launched in the 1980s), with a fully generic global market today.
  • - Covers severe Gram-negative infections including Pseudomonas, addressing large needs such as 49M sepsis cases and 150M UTIs annually.
  • - Listed on the WHO Essential Medicines List (AWaRe Watch); featured in major guidelines as an empiric/targeted anti-pseudomonal option.
  • - PMDA GMP certification and Japanese registration signal high quality and facilitate reliance/accelerated registrations and hospital access in multiple regions.
  • - Broad strengths (0.5/1.0/1.5/2.0/2.5g) reduce wastage and enable precise dosing, improving tender competitiveness and total treatment cost control.

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →